Antibodies to Capsular Polysaccharide and Clumping Factor A Prevent Mastitis and the Emergence of Unencapsulated and Small-Colony Variants of *Staphylococcus aureus* in Mice

Lorena P. N. Tuchscherer,¹ Fernanda R. Buzzola,¹,² Lucia P. Alvarez,¹,² Jean C. Lee,³ and Daniel O. Sordelli¹,²*  

Department of Microbiology, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina;¹ CONICET, Buenos Aires, Argentina;² and Channing Laboratory, Department of Medicine, Brigham & Women’s Hospital, Harvard Medical School, Boston, Massachusetts³  

Received 15 July 2008/Returned for modification 27 August 2008/Accepted 17 September 2008

The pathogenesis of *Staphylococcus aureus* infections is influenced by multiple virulence factors that are expressed under variable conditions, and this has complicated the design of an effective vaccine. Clinical trials that targeted the capsule or clumping factor A (ClfA) failed to protect the recipients against staphylococcal infections. We passively immunized lactating mice with rabbit antibodies to *S. aureus* capsular polysaccharide (CP) serotype 5 (CP5) or CP8 or with monoclonal antibodies to ClfA. Mice immunized with antibodies to CP5 or CP8 or with ClfA had significantly reduced tissue bacterial burdens 4 days after intramammary challenge with encapsulated *S. aureus* strains. After several passages in mice passively immunized with CP-specific antisera, increasing numbers of stable unencapsulated variants of *S. aureus* were cultured from the infected mammary glands. Greater numbers of these unencapsulated *S. aureus* variants than of the corresponding encapsulated parental strains were internalized in vitro in MAC-T bovine cells. Furthermore, small-colony variants (SCVs) were recovered from the infected mammary glands after several passages in mice passively immunized with CP-specific antisera. A combination of antibodies effectively sterilized mammary glands in a significant number of passively immunized mice. More importantly, passive immunization with antibodies to both CP and ClfA fully inhibited the emergence of unencapsulated “escape mutants” and significantly reduced the appearance of SCVs. A vaccine formulation comprising CP conjugates plus a surface-associated protein adhesin may be more effective than either antigen alone for prevention of *S. aureus* infections.

*Staphylococcus aureus* is a highly prevalent, opportunistic, multifactorial pathogen that causes both community-acquired and life-threatening nosocomial infections (28). The control of staphylococcal infections is threatened by the emergence of community-acquired methicillin-resistant *S. aureus* strains (12, 20), as well as strains that show reduced susceptibility to vancomycin (3). Rational design of a staphylococcal vaccine is a logical approach for preventing the morbidity and mortality associated with *S. aureus* infections and for decreasing the medical costs associated with severe staphylococcal disease. Numerous targets have been identified for inclusion in vaccines to prevent *S. aureus* infections in humans, but most of these vaccines are still in the preclinical development stage (35). *S. aureus* capsular polysaccharide (CP) serotype 5 (CP5) and CP8 are produced by ~75% of human isolates, and it has been shown that antibodies to the CPs have some protective efficacy for preventing staphylococcal infections in experimental animals (8, 22). However, two phase III clinical trials of a combined CP5-CP8 conjugate vaccine failed to show a cumulative reduction in episodes of *S. aureus* bacteremia in patients undergoing hemodialysis (38; http://www.nabi.com/pipeline/clinicaltrials.php#1). There were probably numerous factors that were responsible for the failed CP vaccine trials, and these factors are poorly understood. Certainly, a vaccine that targets only encapsulated *S. aureus* does not protect against the 20 to 25% of clinical isolates that lack a capsule. Previous studies have demonstrated that CP is produced in vivo in animal models of staphylococcal infection (19, 23). However, the expression of *S. aureus* CP5 and CP8 is highly sensitive to several environmental signals, including nutrient and iron availability (32). In addition, CP is not expressed by *S. aureus* in the logarithmic phase of growth (32) or in the presence of ≥1% CO₂ (15, 26). Furthermore, CP expression has been shown to be downregulated during chronic staphylococcal lung infection in cystic fibrosis patients (14) and in a guinea pig model of *S. aureus* implant infection (10). We have shown that loss of CP expression facilitates *S. aureus* internalization into bovine epithelial cells (2, 44) and contributes to the persistence of *S. aureus* in infected mammary glands of mice (44). Therefore, development of a vaccine for *S. aureus* requires addition of other bacterial components, as suggested previously (42), to ensure effectiveness with capsule-negative *S. aureus*

Clumping factor A (ClfA) is a cell wall-anchored *S. aureus* surface protein that has been shown to enhance staphylococcal virulence in animal infection models (27, 49). ClfA has been suggested as a vaccine potential candidate (17, 18, 31) and as a target for passive immunization approaches (6, 33, 46). In a phase III clinical trial, 1,983 neonates received either a placebo or INH-A21 (Veronate), a pooled human immunoglobulin
preparation from donors selected on the basis of high antibody titers against staphylococcal \textit{S. aureus} ClfA and \textit{Staphylococcus epidermidis} SdrG. There was no difference between the rates of late-onset sepsis caused by \textit{S. aureus} or coagulase-negative staphylococci in the two groups (5). To date, vaccine trials targeting \textit{S. aureus} have been performed only with immuno-compromised patient populations (hemodialysis patients and premature neonates).

The present study was designed to determine whether antibodies to the \textit{S. aureus} CPs or ClfA, given separately or together, prevent staphylococcal infection in a mouse model of mastitis. This model represents a well-characterized, sublethal, and localized \textit{S. aureus} infection that mimics ruminant mastitis due to similarities between mice and cows (30). We also assessed the phenotype of the staphylococci cultured from the passively immunized animals to determine whether antibodies to CP selected in vivo for the emergence of escape mutants of \textit{S. aureus} that lacked a capsule. Recovery of \textit{S. aureus} small-colony variants (SCVs) from the infected animals passively immunized with CP antiserum was an unanticipated finding.

**MATERIALS AND METHODS**

**Bacterial strains and antibodies.** Bovine \textit{S. aureus} strain RA9 is a capsule serotype 5 strain obtained from a cow with mastitis and was provided by L. Calvinho, Estación Experimental INTA, Santa Fe, Argentina. Bovine strain MBC212 (CP5 positive) and strains Reynolds (CP5) and Reynolds (CP8), derived from serotype 5 human isolate Reynolds, have been described elsewhere (4, 48). \textit{S. aureus} was cultured overnight on tryptic soy agar (TSA) plates (Difco, Detroit, MI). Bacterial suspensions were prepared in phosphate-buffered saline (PBS) and diluted to obtain suspensions containing $2 \times 10^7$ CFU/ml. The species of variants obtained in animal experiments were confirmed by PCR amplification of species-specific sequences as described by Martineau et al. (25).

Antibodies to CP5 or CP8 were obtained by immunization of rabbits with killed encapsulated bacteria as described previously (21), followed by absorption of the sera with unencapsulated mutant strains to make them specific for CP5 or CP8. Preimmune rabbit serum was nonreactive as determined by immunodiffusion with bacterial extracts containing CP5 or CP8. Monoclonal antibodies (MAbs) to ClfA (immunoglobulin G1; Aurexis 904-A1 INH-H06048; lot 27E001-4E7042) were kindly provided by Inhibitex Inc. (Alpharetta, GA) (13, 36).

**Mouse models.** CFI outbred mice were maintained in the vivarium of the Department of Microbiology, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, in accordance with the guidelines of the National Institutes of Health (29). The mouse model of mastitis has been described previously (11, 44). Groups of 8 to 10 mice were passively immunized by the intraperitoneal (i.p.) route with either 0.5 ml of anti-CP5 serum, 0.5 ml of anti-CP8 serum, 0.5 ml of preimmune rabbit serum, or 10 mg/kg of ClfA MAbs. Additional groups of mice received antibodies to both CP5 and ClfA. After 24 h the mice were challenged by injection of $10^7$ CFU \textit{S. aureus} in 50 ml into the left fourth and right fourth mammary glands. After 4 days the left fourth and right fourth mammary glands were excised from each animal and homogenized separately in 2 ml of tryptic soy broth. Dilutions of the homogenates were plated quantitatively on TSA plates. No growth was detected in any cell culture supernatant, indicating that 100% of the extracellular \textit{S. aureus} cells were lysed by lysostaphin. The monolayer was washed four times with sterile PBS, treated for 5 min at 37°C with 100 ml of 0.25% trypsin-0.1% EDTA (Gibco BRL) and lysed by addition of 900 ml of 0.025% Triton X-100 (USB, Cleveland, OH) in sterile distilled water to release intracellular staphylococci. The numbers of CFU/ml in the cell lysates were determined by plating serial dilutions on TSA plates.

**Statistical analyses.** Quantitative culture data for tissue homogenates were compared by using the Mann-Whitney test for nonparametric data. $P$ values of $<0.05$ were considered significant. The Prism 4.0 software (GraphPad) was used for all calculations.

**RESULTS**

**Passive immunization with CP-specific antiserum.** We passively immunized mice i.p. with CP-specific antiserum or nonimmune serum 24 h before intramammary challenge with $10^6$ CFU \textit{S. aureus} (Fig. 1). The challenge strains included bovine isolates RA9 (CP5 positive) and MBC212 (CP8 positive) and human strains Reynolds (CP5) and Reynolds (CP8). Compared to animals given preimmune serum, mice given antibodies to CP5 or CP8 showed significant reductions in the numbers of \textit{S. aureus} CFU recovered from the infected glands after 4 days (Fig. 2). The protective effect of CP antibodies was most striking for bovine isolates MBC212 and RA9 (4-log$_{10}$ reductions in the bacterial burden compared to mice given preimmune serum). Similarly, a 2-log$_{10}$ reduction in the number of CFU/gland was observed for mice passively immunized with...
CP antibodies and challenged with human isolate Reynolds (CP5) or Reynolds (CP8). In vitro experiments performed with strains RA9 and MBC212 indicated that rabbit antiserum to CP5 and rabbit antiserum to CP8, respectively, had no direct effect on *S. aureus* viability (data not shown).

*S. aureus* cells recovered after 4 days from mice given antibodies specific to CP5 or CP8 were injected into another group of passively immunized mice in the second cycle of the experiment (Fig. 1). The cycle of challenge and recovery from the mammary glands was repeated 16 times, and *S. aureus* colonies were tested after each cycle for CP production. All of the colonies recovered from mice given preimmune or immune serum during the first three cycles of passage were CP positive. By the fourth cycle, however, a few colonies of *S. aureus* RA9 cultured from the mammary tissue homogenates of passively immunized mice showed a loss of CP5 production (Fig. 3, upper panel). The percentage of NT *S. aureus* colonies recovered from the infected glands increased rapidly thereafter and reached a plateau (~70%) by the eighth cycle. Similarly, NT *S. aureus* emerged after five or six mouse passages from passively immunized animals challenged with bovine isolate MBC212 (Fig. 3, upper panel) or the isogenic CP5-positive and CP8-positive derivatives of strain Reynolds (Fig. 3, lower panel). With NT derivatives obtained in vivo there was positive PCR amplification for *S. aureus*-specific sequences. In addition, the Smal pulsed-field gel electrophoresis band patterns of NT strains recovered from different mice coincided with those of the encapsulated strains inoculated into the mice in the first cycle of the experiment (not shown). NT *S. aureus* was obtained from mammary gland homogenates of none of the control mice followed for up to 16 passages, and staphylococci were not recovered from the liver, kidneys, spleens, or lungs of mice in either group 4 days after bacterial inoculation. It is noteworthy that the protection afforded by passive immunization with CP-specific antibodies (Fig. 2) was apparent only when most of the *S. aureus* cells recovered from the infected glands were CP positive (i.e., after fewer than six infection cycles) (Fig. 3). The CP antibody-mediated reduction in the bacterial burden decreased thereafter, and there was no decrease in the number of CFU/gland when all of the *S. aureus* cells recovered from the glands were NT (data not shown).

**In vivo reversion of NT S. aureus.** NT *S. aureus* recovered from the mammary glands of mice given CP antiserum did not revert to CP production after 10 in vitro passages on Columbia salt agar, a medium that supports optimal CP expression. To determine whether reversion might occur in vivo, we challenged groups of 6 to 10 nonlactating, naïve mice by the i.p. route with 10^8 CFU of a stable NT derivative of strain RA9. Twenty-four hours later, ~10^3 CFU *S. aureus/ml was recovered from the mouse blood samples. No CP5-positive colonies were detected after the first or second passages. By the third passage, however, 11% of the colonies isolated from the blood expressed CP5. The percentage of CP5-positive *S. aureus* colonies increased to 25% by the fourth cycle and remained unchanged through the 10th cycle of the experiment.

**Passive immunization with MABs to S. aureus ClfA.** Additional groups of lactating mice were passively immunized i.p. with MABs to *S. aureus* ClfA or with isotype-matched control
MAbs. Administration of the ClfA MAbs to mice prior to challenge with bovine strain RA9 (CP5 positive) resulted in a 3-log\(_{10}\) reduction in the tissue bacterial burden compared to that in mice given control MAbs (Fig. 4). Passive immunization with antibodies to both CP5 and ClfA had an additive effect, effectively sterilizing 17 (42%) of 40 mammary glands infected with \(S\). \(aureus\) RA9 during experimental cycles 1 through 4. CP5 and ClfA antibody-mediated protection against infection of the mammary glands persisted for up to 10 infection cycles (data not shown). Moreover, NT \(S\). \(aureus\) colonies were not recovered from the mammary glands of mice passively immunized with ClfA MAbs alone or in combination with CP5 antibodies for up to 10 infection cycles (Fig. 5).

**Internalization in MAC-T cells.** CP-positive \(S\). \(aureus\) strains avoid internalization by professional phagocytes, as well as by other types of mammalian cells (2, 24, 43, 44, 48). Consistent with this observation, the numbers of cells of NT \(S\). \(aureus\) variants (derived from mice passively immunized with CP5 antiserum before challenge with strain RA9) internalized in vitro in MAC-T cells were greater than the numbers of cells of the corresponding encapsulated parental strains internalized (for NT variants, \(1.96 \times 10^6 \pm 0.02 \times 10^6\) CFU/ml of cell lysate; for RA9, \(1.37 \times 10^6 \pm 0.02 \times 10^6\) CFU/ml of cell lysate [arithmetic means ± standard errors of the means]). Each CFU value is the average for 11 wells from a representative experiment. The well-to-well dispersion was extremely low, and the experiment was performed three times with similar results. Likewise, increased internalization of NT \(S\). \(aureus\) was observed in experiments performed with an NT \(S\). \(aureus\) variant derived from mice passively immunized with CP8 antiserum before challenge with strain MBC212 (for the NT variant, \(1.23 \times 10^5 \pm 0.02 \times 10^5\) CFU/ml of cell lysate; for

**FIG. 4.** Passive immunization with antibodies to CP5 and ClfA reduced the intramammary bacterial load 96 h after intramammary challenge. Each bar indicates the mean log\(_{10}\) CFU \(S\). \(aureus\)/gland, and the error bars indicate the standard errors of the means (six to eight mice/group). The dotted line indicates the limit of detection by culture.

**FIG. 5.** Emergence of NT \(S\). \(aureus\) in the mammary glands of mice challenged with \(S\). \(aureus\) strain RA9 (CP5 positive) did not occur in mice inoculated with ClfA MAbs (with or without CP5 antibodies) up to the 10th experimental cycle. Each symbol indicates the percentage of NT \(S\). \(aureus\) colonies obtained after a cycle of enrichment.

**FIG. 6.** Recovery of SCVs from the mammary glands of passively immunized mice during the enrichment experiment. The SCVs were isolated from mice treated with CP antibodies and challenged with bovine isolate RA9 or MBC212 (left panel) or human isogenic strain Reynolds (CP5) or Reynolds (CP8) (right panel). SCVs were recovered from the majority of mice inoculated with the bovine RA9 or MBC212 strain but from only one-half of the mice challenged with Reynolds (CP5) or Reynolds (CP8). SCVs were not detected in tissues from mice inoculated with nonimmune rabbit serum.

MBC212, \(0.39 \times 10^5 \pm 0.01 \times 10^5\) CFU/ml cell of lysate). The results of the present study are consistent with previous results obtained in our laboratory with strains Reynolds (CP5) and Reynolds (CP8) and the isogenic derivative Reynolds (CP−) (44).

**Selection of SCVs by passive immunization with CP-specific antiserum.** All of the mammary glands (8 to 10 glands per enrichment cycle) from mice treated with either CP5- or CP8-specific antiserum and inoculated with bovine strain RA9 (CP5 positive) or MBC212 (CP8 positive) yielded SCVs by the sixth enrichment cycle (Fig. 6, left panel). SCVs also emerged in mice challenged with human strain Reynolds (CP5) or Reynolds (CP8) (Fig. 6, right panel) but not from mice given nonimmune serum. Most SCVs obtained in the sixth cycle reverted to a normal colony phenotype after one or two in vitro subcultures, whereas some SCVs recovered after the ninth cycle exhibited a more stable phenotype that did not revert after seven passages. SCVs were detected only after 48 h of incubation.
tion at 37°C, and the small colonies showed little pigmentation, hemolysis, or coagulate activity (positive only after 18 h of incubation at 37°C). The CP phenotype was assessed for SCVs that emerged in vivo from mice infected with strains RA9 (n = 78), MBC212 (n = 80), Reynolds (CP5) (n = 93), and Reynolds (CP8) (n = 89); all 340 SCVs were CP positive and exhibited positive PCR amplification of S. aureus-specific sequences. The auxotrophies and genetic lesions responsible for the SCV phenotypes of strains recovered from mice with mastitis were not characterized, but they have been described in previous reports and were summarized in a recent review (34). Only a few SCVs were detected in the mammary glands of mice given both CP5 antibodies and ClfA MAbs, and these SCVs were not apparent until the seventh infection cycle (Fig. 7).

**DISCUSSION**

Passive immunization with antibodies to CP5 and CP8 significantly reduced the bacterial load in S. aureus infections in a mouse model of mastitis. Encapsulated staphylococci, opsonized with antibodies to CP, were likely cleared more efficiently from the mammary glands through phagocytic uptake and killing by professional phagocytes recruited to the infection site. This is the first report that documents that antibodies targeting a surface polysaccharide and a cell wall-associated protein provided better protection than either of the antibodies alone. Similar findings were reported by Stranger-Jones et al., who showed that a vaccine comprising multiple S. aureus adhesins provided enhanced protection against mouse lethality compared to any of the individual proteins (42).

Our results also provide evidence that antibodies specific to CP5 or CP8 promoted selection and emergence of NT S. aureus in vivo. Although several mechanisms can explain the loss of CP expression by S. aureus, point mutations in essential cap5 and cap8 genes are most prevalent in NT human and bovine isolates (4, 41, 45). Alternatively, loss of CP expression by S. aureus in mice passively immunized with antibodies to CP5 or CP8 may result from mutations in regulatory genes like agr or arlRS. Most of the NT derivatives obtained in our study were hemolytic, suggesting that they were not agr mutants. In the absence of the selective pressure provided by antibodies to CP, the CP5-positive phenotype was restored in the bloodstream of nonimmune mice challenged with the experimental NT variants.

Thakker et al. (43) demonstrated the critical role played by CP in staphylococcal bloodstream infection since CP5-positive S. aureus resulted in a higher level of mouse bacteremia than unencapsulated mutants. In contrast, CP5 and CP8 attenuated virulence in a mouse model of staphylococcal mastitis and reduced internalization by bovine mammary epithelial cells in vitro (2, 44). Thus, S. aureus readily adapts to its microenvironment; CP-expressing bacterial cells survive in the bloodstream, whereas unencapsulated variants adhere, invade, and selectively persist within infected tissues. Our findings suggest that antibodies to CP5 and CP8 may enhance the clearance of encapsulated S. aureus from infected mice but, at the same time, select for a bacterial subpopulation (unencapsulated) that can be internalized within epithelial cells, thereby avoiding further immune clearance.

S. aureus SCVs have been implicated in chronic and persistent staphylococcal infections (1) and in S. aureus intracellular survival (9, 40, 47). Our study demonstrated that selective pressure exerted in vivo by antibodies to CP5 and CP8 led to the emergence of NT variants and SCVs. Whereas it is logical that NT “escape mutants” might emerge in the presence of antibodies to CP5 or CP8, it is not apparent how administration of these antibodies resulted in the emergence in vivo of SCVs. It is possible that NT variants of S. aureus were internalized within epithelial cells and that this facilitated evolution of SCVs in the intracellular milieu. However, our SCVs expressed CP5, consistent with previous investigations that showed that there was upregulation of capsule genes in S. aureus SCVs (37). The emergence of stable NT S. aureus variants and the emergence of SCVs in our mouse infection model seemed to be independent phenomena, since such variants were isolated simultaneously from the infected glands of lactating mice. The environmental factors that trigger SCV formation are poorly understood. It is possible that downregulation of CP expression in vivo may generate unstable NT phenotypes that are internalized within epithelial cells. Once in the intracellular milieu, the NT S. aureus variants may evolve into SCVs and regain CP expression. This scenario might ex-
plain the concomitant emergence of stable NT S. aureus variants and CP-positive SCVs in our mastitis infection model.

We conclude that a vaccine formulation comprising CP conjugates plus a surface-associate protein adhesin may be more effective than either antigen alone for prevention of S. aureus infections. We showed that antibodies to ClfA enhanced the protection against infection provided by antibodies to the CPs. Furthermore, administration of antibodies to CP and ClfA abrogated the emergence of NT S. aureus and decreased the recovery of SCVs from the infected mouse tissues. Whether this combination of antibodies protects against other types of staphylococcal infections merits further investigation.

ACKNOWLEDGMENTS

This study was partially supported by grants from the NIH Fogarty Foundation (grant FIRCIA 1-R03-TW006264) and the NIAID (grant RO1 AI203040) to J.C.L., from the Agencia Nacional de Promoción de la Ciencia y la Tecnología, Argentina (grants ANPCyT PICT 05-10648 and ANPCyT PICT 05-32577), and from the Secretaría de Ciencia y Técnica, Universidad de Buenos Aires, Argentina (grant UBAICYT M-070).

We thank Joseph M. Patti, Inhibitex, Inc., Alpharetta, GA, for providing CIA Mabs (Aurexis). We also thank Lorena Medina for her dedicated technical assistance and Sabrina Soldavini for her assistance with animal experiments.

REFERENCES


Downloaded from http://iai.asm.org/ on August 15, 2017 by guest

ABSTRACTS TO CAPSULE AND S. AUREUS MASTITIS 5743


Editor: V. J. DiRita